Cargando…

ANCA Vasculitis Induction Management During the COVID-19 Pandemic

Detalles Bibliográficos
Autores principales:	Salas, Antonio, Kant, Sam, Floyd, Lauren, Kratky, Vojtěch, Brix, Silke R., Prendecki, Maria, Schönermarck, Ulf, Scott, Jennifer, Saha, Manish, Gauckler, Philipp, Li, Tingting, Sharma, Purva D., Ayoub, Isabelle, Morris, Adam D., Dhaygude, Ajay P., Hruskova, Zdenka, Tesar, Vladimir, McAdoo, Stephen P., Little, Mark A., Derebail, Vimal K., Poulton, Caroline J., Seo, Philip, Kronbichler, Andreas, Geetha, Duvuru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373584/ https://www.ncbi.nlm.nih.gov/pubmed/34426797 http://dx.doi.org/10.1016/j.ekir.2021.08.009

Ejemplares similares

Complement Inhibition in ANCA-Associated Vasculitis
por: Tesar, Vladimir, et al.
Publicado: (2022)

The impact of COVID-19 pandemic on patients with ANCA associated vasculitis
por: Kant, Sam, et al.
Publicado: (2020)

Comorbidities in ANCA-associated vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

ANCA Status or Clinical Phenotype — What Counts More?
por: Windpessl, Martin, et al.
Publicado: (2021)

Risk factors for serious infections in ANCA-associated vasculitis
por: Odler, Balazs, et al.
Publicado: (2023)

Levamisole adulterated cocaine associated ANCA vasculitis: review of literature and update on pathogenesis
por: Jin, Qiuyu, et al.
Publicado: (2018)

Long-term outcome of patients with ANCA-associated vasculitis treated with plasma exchange: a retrospective, single-centre study
por: Frausová, Doubravka, et al.
Publicado: (2016)

Challenges of defining renal response in ANCA-associated vasculitis: call to action?
por: Odler, Balazs, et al.
Publicado: (2023)

ANCA Associated Vasculitis Subtypes: Response [Response to Letter]
por: Austin, Keziah, et al.
Publicado: (2022)

The COVID-19 pandemic and ANCA-associated vasculitis – reports from the EUVAS meeting and EUVAS education forum
por: Kronbichler, Andreas, et al.
Publicado: (2021)

SARS-CoV-2 Vaccine Response in Patients With Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis
por: Floyd, Lauren, et al.
Publicado: (2021)

Immune checkpoint inhibitors as potential triggers for ANCA vasculitis
por: Aqeel, Faten, et al.
Publicado: (2022)

ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives
por: Austin, Keziah, et al.
Publicado: (2022)

Serum chitinase-3-like 1 protein is a useful biomarker to assess disease activity in ANCA-associated vasculitis: an observational study
por: Ahn, Sung Soo, et al.
Publicado: (2021)

Comparisons of Guidelines and Recommendations on Managing Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: Geetha, Duvuru, et al.
Publicado: (2018)

Subcutaneous Immunoglobulin for Antibody Deficiency in Antineutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis
por: Kant, Sam, et al.
Publicado: (2019)

Cardiovascular disease and ANCA-associated vasculitis: are we missing a beat?
por: Floyd, Lauren, et al.
Publicado: (2022)

Analysis of microRNAs in Small Urinary Extracellular Vesicles and Their Potential Roles in Pathogenesis of Renal ANCA-Associated Vasculitis
por: Frydlova, Jana, et al.
Publicado: (2022)

Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients
por: McAdoo, Stephen P., et al.
Publicado: (2017)

Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course
por: Tariq, Anam, et al.
Publicado: (2022)

Older patients with ANCA-associated vasculitis and dialysis dependent renal failure: a retrospective study
por: Manno, Rebecca L., et al.
Publicado: (2015)

Application of the ANCA Renal Risk Score in the United States: A Single-Center Experience
por: Kant, Sam, et al.
Publicado: (2021)

Outcomes of COVID-19 in patients with ANCA-associated vasculitis receiving avacopan
por: Aqeel, Faten, et al.
Publicado: (2023)

Recent advances in understanding of the pathogenesis of ANCA-associated vasculitis
por: Prendecki, Maria, et al.
Publicado: (2018)

Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series
por: McAdoo, Stephen P., et al.
Publicado: (2016)

Patient Outcomes in Renal-Limited Antineutrophil Cytoplasmic Antibody Vasculitis With Inactive Histology
por: Novick, Tessa K., et al.
Publicado: (2018)

Low-Dose Intravenous Methylprednisolone in Remission Induction Therapy for ANCA-Associated Vasculitis
por: Floyd, Lauren, et al.
Publicado: (2023)

Immunopathogenesis of ANCA-Associated Vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

Biomarkers of fibrosis, kidney tissue injury and inflammation may predict severity and outcome of renal ANCA – associated vasculitis
por: Satrapova, Veronika, et al.
Publicado: (2023)

Frailty assessment in ANCA-associated vasculitis: current evidence and remaining uncertainties
por: Wang, Choon Ying, et al.
Publicado: (2022)

COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab
por: Bruchfeld, Annette, et al.
Publicado: (2021)

Increased Levels of Soluble ST2 in Patients with Active Newly Diagnosed ANCA-Associated Vasculitis
por: Hladinova, Z., et al.
Publicado: (2015)

Danger-associated molecular pattern molecules and the receptor for advanced glycation end products enhance ANCA-induced responses
por: Page, Theresa H, et al.
Publicado: (2021)

Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives
por: Hartinger, Jan Miroslav, et al.
Publicado: (2022)

Impact of rituximab on humoral response to COVID-19 booster vaccine and antibody kinetics in patients with anti–neutrophil cytoplasmic antibody vasculitis
por: Kant, Sam, et al.
Publicado: (2021)

What comes after the lockdown? Clustering of ANCA-associated vasculitis: single-centre observation of a spatiotemporal pattern
por: Gauckler, Philipp, et al.
Publicado: (2021)

COVID-19 vaccination in patients with immunity-mediated kidney disease
por: Prendecki, Maria, et al.
Publicado: (2021)

Endotrophin, a collagen type VI-derived matrikine, reflects the degree of renal fibrosis in patients with IgA nephropathy and in patients with ANCA-associated vasculitis
por: Sparding, Nadja, et al.
Publicado: (2021)

Nasal microbiome research in ANCA-associated vasculitis: Strengths, limitations, and future directions
por: Kronbichler, Andreas, et al.
Publicado: (2020)

Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti–neutrophil cytoplasmic antibody–associated vasculitis
por: Kant, Sam, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e7lb8f4uoptjd9okc90vqgor9r